FRLN — Freeline Therapeutics Holdings Share News
0.000.00%
Last trade - 00:00Freeline Therapeutics rises after starting bleeding disorder therapy trial
Brief: Freeline Announces First Patient Dosed In The Phase 1/2 B-Lieve Dose-Confirmation Trial In Hemophilia B
Brief: Freeline Presents On Its Fabry And Gaucher Disease AAV-Based Gene Therapies
Syncona Limited - Freeline presents data in Fabry disease
U.S. STOCKS ON THE MOVE-Chinese stocks, Rivian, Bath & Bodyworks, Allbirds, Nikola
U.S. STOCKS ON THE MOVE-Rivian, JD.com, Plus Therapeutics, Bed Bath & Beyond
U.S. STOCKS ON THE MOVE-Western Union, Rivian, Netflix, Alterity Therapeutics
Brief: Freeline Announces FDA Clearance Of IND Application For FLT201 For Gaucher Disease Type 1
Freeline Therapeutics soars as FDA clears new drug application
Syncona Limited - Freeline reports 2022 priorities and guidance
Brief: Freeline Announces 2022 Corporate Priorities And Guidance
Brief: Freeline Presents Long-Term Follow-Up Data From Phase 1/2 B-AMAZE Trial In Hemophilia B
Syncona Limited - Freeline presents data in haemophilia B
Brief: Freeline Therapeutics Holdings Says May Offer ADSS Having Aggregate Offering Price Of Up To $75 Mln From Time To Time Through Jefferies
Syncona Limited - Freeline reports new data and 3rd Quarter Results
Brief: Freeline Reports New Data From Fabry Disease Program
Brief: Freeline Therapeutics Holdings Files For Mixed Shelf Of Up To $250 Million
Brief: Freeline Therapeutics Holdings - Both U.S. FDA And European Commission Have Granted Orphan Drug Designation For Flt201 For Treatment Of Gaucher Disease.
U.S. FDA remains highly supportive of gene therapies - Mizuho